Home Healthcare Pharmaceuticals Glioblastoma Multiforme (GBM) Treatment Market

Glioblastoma Multiforme (GBM) Treatment Market Size, Share & Trends Analysis Report By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy), By Drugs (Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Others), By End-User (Hospitals, Clinics, Ambulatory Surgical Centers) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Debashree B | Format: | Report Code: SR4657DR | Pages: 155
Overview TOC Segmentation Methodology
Download Free Sample

Table Of Content

  1. Executive Summary
  2. Research Scope & Segmentation
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
  3. Market Opportunity Assessment
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
  4. Market Trends
    1. Drivers
    2. Market Warning Factors
    3. Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
  5. Market Assessment
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
  6. Glioblastoma Multiforme (GBM) Treatment Market Size Analysis
    1. Introduction
    2. Glioblastoma Multiforme (GBM) Treatment Market Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
      1. Surgery
      2. Radiation Therapy
      3. Chemotherapy
      4. Targeted Therapy
      5. Tumor Treating Field (TTF) Therapy
      6. Immunotherapy
    3. Glioblastoma Multiforme (GBM) Treatment Market Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
      1. Temozolomide
      2. Bevacizumab
      3. Lomustine
      4. Carmustine Wafers
      5. Others
    4. Glioblastoma Multiforme (GBM) Treatment Market Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Clinics
      3. Ambulatory Surgical Centers
  7. North America Glioblastoma Multiforme (GBM) Treatment Market Size Analysis
    1. Introduction
    2. Glioblastoma Multiforme (GBM) Treatment Market Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
      1. Surgery
      2. Radiation Therapy
      3. Chemotherapy
      4. Targeted Therapy
      5. Tumor Treating Field (TTF) Therapy
      6. Immunotherapy
    3. Glioblastoma Multiforme (GBM) Treatment Market Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
      1. Temozolomide
      2. Bevacizumab
      3. Lomustine
      4. Carmustine Wafers
      5. Others
    4. Glioblastoma Multiforme (GBM) Treatment Market Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Clinics
      3. Ambulatory Surgical Centers
    5. U.S.
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    6. Canada
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
  8. Europe Glioblastoma Multiforme (GBM) Treatment Market Size Analysis
    1. Introduction
    2. Glioblastoma Multiforme (GBM) Treatment Market Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
      1. Surgery
      2. Radiation Therapy
      3. Chemotherapy
      4. Targeted Therapy
      5. Tumor Treating Field (TTF) Therapy
      6. Immunotherapy
    3. Glioblastoma Multiforme (GBM) Treatment Market Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
      1. Temozolomide
      2. Bevacizumab
      3. Lomustine
      4. Carmustine Wafers
      5. Others
    4. Glioblastoma Multiforme (GBM) Treatment Market Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Clinics
      3. Ambulatory Surgical Centers
    5. U.K.
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    6. Germany
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    7. France
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    8. Spain
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    9. Italy
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    10. Russia
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    11. Nordic
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    12. Benelux
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    13. Rest of Europe
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
  9. APAC Glioblastoma Multiforme (GBM) Treatment Market Size Analysis
    1. Introduction
    2. Glioblastoma Multiforme (GBM) Treatment Market Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
      1. Surgery
      2. Radiation Therapy
      3. Chemotherapy
      4. Targeted Therapy
      5. Tumor Treating Field (TTF) Therapy
      6. Immunotherapy
    3. Glioblastoma Multiforme (GBM) Treatment Market Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
      1. Temozolomide
      2. Bevacizumab
      3. Lomustine
      4. Carmustine Wafers
      5. Others
    4. Glioblastoma Multiforme (GBM) Treatment Market Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Clinics
      3. Ambulatory Surgical Centers
    5. China
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    6. Korea
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    7. Japan
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    8. India
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    9. Australia
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    10. Taiwan
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    11. South East Asia
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    12. Rest of Asia-Pacific
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
  10. Middle East and Africa Glioblastoma Multiforme (GBM) Treatment Market Size Analysis
    1. Introduction
    2. Glioblastoma Multiforme (GBM) Treatment Market Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
      1. Surgery
      2. Radiation Therapy
      3. Chemotherapy
      4. Targeted Therapy
      5. Tumor Treating Field (TTF) Therapy
      6. Immunotherapy
    3. Glioblastoma Multiforme (GBM) Treatment Market Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
      1. Temozolomide
      2. Bevacizumab
      3. Lomustine
      4. Carmustine Wafers
      5. Others
    4. Glioblastoma Multiforme (GBM) Treatment Market Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Clinics
      3. Ambulatory Surgical Centers
    5. UAE
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    6. Turkey
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    7. Saudi Arabia
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    8. South Africa
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    9. Egypt
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    10. Nigeria
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    11. Rest of MEA
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
  11. LATAM Glioblastoma Multiforme (GBM) Treatment Market Size Analysis
    1. Introduction
    2. Glioblastoma Multiforme (GBM) Treatment Market Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
      1. Surgery
      2. Radiation Therapy
      3. Chemotherapy
      4. Targeted Therapy
      5. Tumor Treating Field (TTF) Therapy
      6. Immunotherapy
    3. Glioblastoma Multiforme (GBM) Treatment Market Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
      1. Temozolomide
      2. Bevacizumab
      3. Lomustine
      4. Carmustine Wafers
      5. Others
    4. Glioblastoma Multiforme (GBM) Treatment Market Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Clinics
      3. Ambulatory Surgical Centers
    5. Brazil
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    6. Mexico
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    7. Argentina
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    8. Chile
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    9. Colombia
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
    10. Rest of LATAM
      1. Introduction
      2. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Surgery
        2. Radiation Therapy
        3. Chemotherapy
        4. Targeted Therapy
        5. Tumor Treating Field (TTF) Therapy
        6. Immunotherapy
      3. Market Size & Forecast By Drugs 2022-2034 (USD MILLION/ Units)
        1. Temozolomide
        2. Bevacizumab
        3. Lomustine
        4. Carmustine Wafers
        5. Others
      4. Market Size & Forecast By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Clinics
        3. Ambulatory Surgical Centers
  12. Competitive Landscape
    1. Glioblastoma Multiforme (GBM) Treatment Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    3. Tier Structure Analysis
    4. Recent Developments
  13. Market Players Assessment
    1. Merck & Co. Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. F. Hoffmann-La Roche Ltd.
    3. Pfizer Inc.
    4. Amgen Inc.
    5. Sun Pharmaceutical Industries Ltd.
    6. Teva Pharmaceutical Industries Ltd.
    7. Arbor Pharmaceuticals LLC
    8. Karyopharm Therapeutics Inc.
    9. Amneal Pharmaceuticals
    10. Sumitomo Dainippon Pharma Oncology Inc. (Boston Biomedical Inc.).
  14. Research Methodology
    1. Research Data
      1. Secondary Data
        1. Major Secondary Sources
        2. Key Data from Secondary Sources
      2. Primary Data
        1. Key Data from Primary Sources
        2. Breakdown of Primaries
      3. Secondary And Primary Research
        1. Key Industry Insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
  15. Appendix
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  16. Disclaimer
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.